Keytruda 50 mg/vial lyophilized powder for injection Images

Generic Name: pembrolizumab

This medication has been identified as Keytruda 50 mg/vial lyophilized powder for injection. It is supplied by Merck.

Keytruda is used in the treatment of Bladder Cancer; Breast Cancer; Biliary Tract Tumor; Cervical Cancer; Colorectal Cancer and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). There is positive evidence of human fetal risk during pregnancy. Keytruda 50 mg/vial lyophilized powder for injection is not a controlled substance under the Controlled Substances Act (CSA).

Images of medication

Keytruda

Generic Name

pembrolizumab

Strength

50 mg/vial lyophilized powder for injection

Availability

Prescription only

Drug Class

Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Pregnancy Category

D - Positive evidence of risk

CSA Schedule

Not a controlled drug

Labeler / Supplier

Merck

National Drug Code (NDC)

00006-3029 (Discontinued)

Drug Uses Add to Drug List Print

Get help with Imprint Code FAQs.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer